Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111187 | 0.92 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL111186 | 0.90 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4731536 | 0.89 | CA1 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL654773 | 0.87 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL9494959 | 0.85 | CA1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1976289 | 0.85 | CA5A (0.52) | CA2KDM4ELMNATDP1L3MBTL1 | |
| SCHEMBL10600019 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2205901 | 0.84 | KDM4E (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28312240 | 0.82 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8410461 | 0.82 | ATAD2 (0.60) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | SAVID THERAPEUTICS INC. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170107562-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-04-20 | — | — | US | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-6630496-B1 | Antiinflammatory agents inhibit phospholipase 2, affecting both protaglandin and leukotriene production; indoles substituted in 2 position by 2,4-dioxo-thiazol-3-yl methylidene | GENETICS INSTITUTE LLC | 2003-10-07 | — | — | US | disclosed |
| EP-1062216-A1 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INSTITUTE, INC. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999043672-A9 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INST (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999043672-A1 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0922028-A1 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998008818-A1 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | BTD, HLCS, BROX | CA12 4074/4885CA1 4877/4885CA2 4868/4885 |
| US-20160002268-A1 | ZINC COMPLEX | SLC39A11, SLC39A3, SOD1 | CA12 1565/4885CA1 1743/4885CA2 3391/4885 |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NUDT1, PNP, NME2 | CA12 3509/4885CA1 3651/4885CA2 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.